ADVANZ PHARMA Corp. Limited, a global pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with enhanced access to high quality, niche-established medicines, announced it signed a definitive agreement to acquire the rights to a portfolio of alprostadil products in 10 European Union countries, as well as the United Kingdom, Russia, Ukraine and Brazil, from UCB S.A.
The transaction has a purchase price of $84 million and ADVANZ PHARMA intends to pay for the acquisition with cash on hand. On closing, ADVANZ PHARMA will also pay a deposit for inventory of approximately $14 million. The Company anticipates that the acquisition will close on, or around, April 1, 2020.
“We believe these medicines are excellent strategic fits with our global commercial infrastructure and are well aligned with our product acquisition focus,” said Graeme Duncan, Chief Executive Officer of ADVANZ PHARMA. “In addition, we believe that the acquisition multiple demonstrates our disciplined and structured approach to M&A, as well as our ability to effectively compete in the divestment market.”
Combined sales of all alprostadil brands generated approximately $33.3 million in revenue in 2019 in the territories where ADVANZ PHARMA will hold the rights.
Looking ahead, with a clear strategic focus, ADVANZ PHARMA believes it will have additional opportunities to expand its product portfolio to deliver mid-term value and long-term growth, through further product and platform acquisitions, and pipeline expansion.
The Company intends to focus on niche and differentiated generics, complex specialty and value-added medicines.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.